BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
RESEARCH & DEVELOPMENT: Specific affinity ligands for targeting therapeutic proteins
Large scale plasma Avidiplas purification
Therapeutic protein screening from yeast, plasma and transgenic milk
PRODUCTS ON MARKET: Mimetic affinity adsorbents
Bioprocess chromatography media
mAB binding adsorbents
PRODUCTS IN DEVELOPMENT: Name Status
PBI-1402 for peripheral arterial disease in Phase Ib/II clinicals
PBI-1393 ready to begin clinicals
Proteus SA
70, allee Graham Bell, Parc Georges Besse
Nimes 30000, France
Phone: +33 (0)4 66 70 64 64; Fax: +33 (0)4 66 70 64 60
Web: www.proteus.fr
E-mail: info@proteus.fr
KEY PERSONNEL: Daniel Dupret; Chairman, President and CEO
Marc Vander Linden; CFO
Gilles Ravot; CSO
Jean-Marie Sonet; VP, Business Development and Marketing
Jean Francois Bloch; VP; Intellectual Property and Licensing
EMPLOYEES: 37 employees
HISTORY: Founded and began biotech R&D in 1998
FACILITIES: 2,500 sq. m. R&D facility
STOCK-FINANCIAL HISTORY: Privately held
PRINCIPAL INVESTORS: Axa Placement Innovation
FCJE
Natexis Ventech
Sofilars
Sofimac
Soridec
Viveris Management
BUSINESS STRATEGY: Contract research
A strategic biotech R&D resource for the industry
AGREEMENTS: Name Products Content of Agreement Date
Aventis Animal enzymes for animal R&D agreement 1999
Nutrition
feed
CEA LETI
biochips for biodefense collaborative R&D 2000
(Commissariat a
l’energie
atomique)
agreement
Degussa enzymes for specialty R&D agreements 1999
chemistry
and alliance
2000
2004
ELF extremophilic micro- screening for novel 1999
organism
enzyme from
extremophilic microorganism
Girffioth
extremophilic micro- screening for novel 2000
University, organism
enzyme from
Brisbane,
extremophilic micro-
Australia
organism
Copyright ©2006 AHC Media ® 331